Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19730392 | 0.94 | GABRA2 (0.53) | GABRA2GABRB2ERCC1ERCC4 | |
| SCHEMBL19730400 | 0.88 | — | — | |
| SCHEMBL19730389 | 0.85 | GABRA2 (0.51) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL19730393 | 0.83 | TSPO (0.52) | — | |
| SCHEMBL19730398 | 0.81 | GABRA2 (0.49) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL1430336 | 0.78 | GABRA2 (0.63) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL19730397 | 0.76 | SLC2A2 (0.55) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL19730391 | 0.72 | — | — | |
| SCHEMBL8150 | 0.71 | GABRA2 (0.70) | GABRA2GABRB2SLC2A2 | |
| SCHEMBL2933100 | 0.70 | SLC2A2 (0.86) | GABRA2GABRB2SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202376-B2 | Heterocyclic compound | GRIN2A, GRIN1, GRIN2B | GABRA2 39/4885GABRB2 61/4885SLC2A2 4177/4885 |
| US-20170362223-A1 | HETEROCYCLIC COMPOUND | GRIN2A, GRIN1, GRIN2B | GABRA2 39/4885GABRB2 61/4885SLC2A2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.